Disc Medicine (IRON) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Disc Medicine (IRON) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 13.5% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with -45.5% for IRON. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.52 billion vs $2.41 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | NAMS |
|---|---|---|
| Share price | $62.75 | $21.57 |
| Market cap | $2.41B | $2.52B |
| 1-day change | +3.25% | +1.43% |
| YTD return | -23.47% | -39.40% |
| 1-year return | -13.53% | -35.30% |
| 5-year return | -45.55% | +117.16% |
| EPS (TTM) | $-6.58 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | $-212.18M | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $99.50 | $42.21 |
| 52-week low | $40.00 | $20.91 |
| Distance from 52-week high | -36.94% | -48.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +64.43% | +130.23% |
| Average volume | 471.18K | 1.36M |
| Shares outstanding | 38.39M | 116.90M |
| Employees | 165 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRON has outperformed NAMS by 21.8 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
IRON vs NAMS FAQ
Which is bigger, Disc Medicine or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.52B compared with $2.41B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or NAMS?
IRON returned -13.53% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.